264 results about "Amphotericin B" patented technology

A composition includes particles including at least about 95 wt % of amphotericin B, wherein the particles have a mass median diameter ranging from about 1.1 μm to about 1.9 μm. Another composition also includes particles including at least about 95 wt % of amphotericin B, wherein at least about 80 wt % of the particles have a geometric diameter ranging from about 1.1 μm to about 1.9 μm. Yet another composition includes particles including amphotericin B, wherein the particles have a mass median diameter less than about 1.9 μm, and wherein the amphotericin B has a crystallinity level of at least about 20%. Unit dosage forms, delivery systems, and methods may involve similar compositions.

The present invention relates to the topical and oral delivery of a composition comprising one or more active agents for treating a disease or symptoms in a subject. In some embodiments, the present invention comprises a composition comprising at least one active compound, e.g., finasteride or minoxidil, and one or more lipids. In some embodiments, the present invention relates to composition and method of preparation for treating androgenic alopecia (AGA), prevention of hair loss and female hirsutism. In some embodiment, the present invention comprises finasteride and at least one lipid component for the treatment of benign prostatic hyperplasia. In some embodiment, the present invention comprises tacrolimus or amphotericin B and at least one lipid component for the treatment of skin or eye related diseases. The present invention provides a method of preparation of a composition comprising at least one active compound and at least one lipid and administering the composition to a subject by oral or topical delivery. In certain embodiments the subject is a mammal. In certain preferred embodiment, the subject is human.

Formulations are provided for pulmonary administration of an antifungal agent to a patient. Methods of using the formulations in the treatment of antifungal infections are also provided, including treatment of pulmonary aspergillosis with amphotericin B-containing formulations. Methods of manufacturing the formulations to achieve optimum properties are provided as well.

This invention relates to a method of treating otitis externa, and in particular otitis externa of fungal etiology, using topical medication, including antifungal agents such as, for example fluconazole, voriconazole, itraconazole, clotrimazole, amphotericin B, caspofungin (Cancidas®), micafungin (Mycamine®), terbinafine, naftifine, butenafine, amorolfine, ravuconazole, posaconazole, flucytosine, econazole, enilaconazole, miconazole, oxiconazole, saperconazole, sulconazole, terconazole, tioconazole, nikkomycin Z, anidulafungin (LY303366), nystatin, pimaricin, griseofulvin, ciclopirox, haloprogin, tolnaftate, and undecylenate.

The invention provides a method for in vitro culture of porcine oocytes, which comprises the steps of ovary acquisition, acquisition of oocytes from an ovary, screening of the oocytes, and maturation culture. The method is characterized in that the acquired ovary is stored in a container of physiological saline for preservation before the step of the acquisition of the oocytes; and the temperature in the container is maintained to between 32 and 34 DEG C; an egg washing liquid adopted in the step of the screening of the oocytes contains amphotericin B with a concentration of between 1 and 10mu g / mL, and serum with a volume percentage of between 2 and 20 percent v / v; and the maturation medium adopted in the step of the maturation culture of the oocytes contains a TCM-199[1X] basic medium with a volume percentage of between 50 and 90 percent v / v, hGG with an antibody titer of between 5 and 25IU / mL and PMSG with an antibody titer of between 5 and 20IU / mL. The method can solve the problems that the prior in vitro maturation technology of the porcine oocytes has long period, is not good for mass production, and has low maturation rate after the culture.

The invention which belongs to the biotechnical field concretely relates to a brain targeted AmB polymer micelle administration system. The brain targeted AmB polymer micelle administration system is prepared by utilizing brain targeted head base Angiopep-2 modified polymer micelles extremely having a clinical application potential, and entrapping micromolecular hydrophobic drugs. The prepared brain targeted AmB polymer micelle administration system can effectively improve the uptaking of the hydrophobic drugs on brain capillary endothelial cells, and can effectively improve the accumulation amount of the drugs in the brain and the brain entrance efficiency of the drugs especially in a noninvasive intravenous injection mode; compared with present clinical preparations of the drugs, such as AmB for injection, the system of the invention has a substantially improved brain targeting efficiency; and the constructed polymer micelle administration system can obviously reduce the hemolyticity and the cytotoxicity of the AmB. The Angiopep-2 modified brain targeted AmB polymer micelle administration system of the invention can be used to promote the accumulation of hydrophobic drugs with low brain entrance efficiencies in the brain.

The antifungal and cancer cell growth inhibitory activities of 1-(3′,4′,5′-trimethoxyphenyl)-2-nitro-ethylene (TMPN) were examined. TMPN was fungicidal for the majority of 132 reference strains and clinical isolates tested, including those resistant to fluconazole, ketoconazole, amphotericin B or flucytosine. Minimum fungicidal concentration / minimum inhibitory concentration (MFC / MIC) ratios were ≦2 for 96% of Cryptococcus neoformans clinical isolates and 71% of Candida albicans clinical isolates. TMPN was fungicidal for a variety of other basidiomycetes, endomycetes and hyphomycetes, and its activity was unaffected by alterations in media pH. TMPN was slightly cytotoxic for murine and human cancer cell lines (GI50=1-4 μg / ml), and weakly inhibited mammalian tubulin polymerization (IC50=0.60 μg / ml). TMPN may also be used as a biochemical probe for tubulin and fungal dimorphism studies.

Provided are methods and compositions for reducing the toxicity of certain hydrophobic therapeutic agents, especially polyene antibiotics, in particular, Amphotericin B (AmB), and therapeutics such as paclitaxel, tamoxifen, an acylated prodrug or an acylated cis-platin, by incorporating these agents within micelles comprising an amphiphilic block-forming copolymer. Where the polyene is amphotericin B, desirably the spacer is an alkyl molecule of aabout 2 to about 8 carbon atoms, desirably 6 carbon atoms, and the core is an N-alkyl molecule of about 8 to about 28 carbon atoms, desirably 12 to 22 carbon atoms, advantageously, 12 to 18 carbon atoms, and as specifically embodied, 18 carbon atoms (stearate moiety). For the formulation of a larger polyene, the spacer and core are proportionately larger than those for amphotericin B. As specifically exemplified herein, the polymer backbone is a PEO of about 270 units with about 10-30 core-forming PLAA subunits, and advantageously about 14-24. Desirably the stearate moiety has a substitution level on the copolymer from about 35 percent to about 70 percent.

This invention relates to a method of treating otitis externa using a topical combination medication, including one or more antifungal agent such as, for example fluconazole, voriconazole, itraconazole, clotrimazole, amphotericin B, caspofungin, micafungin, terbinafine, naftifine, butenafine, amorolfine, ravuconazole, posaconazole, flucytosine, econazole, enilaconazole, miconazole, oxiconazole, saperconazole, sulconazole, terconazole, tioconazole, nikkomycin Z, anidulafungin (LY303366), nystatin, pimaricin, griseofulvin, ciclopirox, haloprogin, tolnaftate, and undecylenate and one or more antibacterial agent such as neomycin sulfate, polymyxin B sulfate, colistin sulfate, gentamycin, tobramycin, chloramphenicol, Ciprofloxacin, Ofloxacin, a penicillin compound, a cephalosporin compound, a macrolide compound, a fluoroquinolone compound, streptomycin, or kanamycin.

The invention discloses a cell culture medium. The raw material formula of the cell culture medium comprises 33.33ml of DMEM / High Glucose (DMEM high-glucose culture medium), 66.67ml of HAM'S / F-12 culture medium, 3-5mg / mL of plant-origin recombinant human serum albumin, 100U / ml of penicillin, 100 micrograms / milliliter of streptomycin, 2.5 micrograms / milliliter of amphotericin B, 0.2-0.5 micrograms / milliliter of hydrocortisone, 3-6 micrograms / milliliter of insulin, 6-10ng / ml of cholera toxin B, 9-12ng / ml of human epidermal growth factor EGF, 22-25 micrograms / milliliter of adenine, and 7-9 micromoles / liter of Y-27632. The cell culture medium can be used for culturing primary human tumor cells or tumor stem cells. The cell culture medium is improved; when the cell culture medium is applied to culturing the primary human tumor cells or the tumor stem cells, the cell culture medium is capable of better accelerating the growth of the primary tumor cells and obtaining the human tumor stem cells of a higher ratio.

The invention discloses a method for preparing high-purity amphotericin B by amphotericin B broth. The amphotericin B crystal powder prepared by the invention has a content of above 970 gamma / mg by biological potency detection, and a content of above 95% by HPLC detection, has low impurity content, and is applicable to industrial production.

The present invention relates to the new use of an already known biomolecule methyl-beta-orcinol carboxylate of formula 1 isolated from a lichen (Everniastrum cirrhatum), for treating pathogenic fungal infections of humans that are resistant to polyene and azole antibiotics such as amphotericin B, nystatin, clotrimazole etc.

The invention discloses recombined streptomyces nodosus capable of producing amphotericin B and application thereof. The recombined streptomyces nodosus is obtained by introducing a kanamycin resistance gene sequence showed in SEQ ID NO.1 into streptomyces nodosus ZJB2016050; by introducing the kanamycin resistance gene, produced strains which have no resistance previously have kanamycin resistance, the purity and quality of the strains of seed culture mediums are improved, and strain contamination phenomena can be prevented from occurring during seed cultivation in a lab. By expressing a function gene, namely vitreoscilla hemoglobin (vhb), the yield of AmB is increased by 15%; by expressing a function gene, namely the S- adenosylmethionine synthetase gene (metk), the yield of AmB is increased by about 40%.

The invention relates to the technical field of medicaments, in particular to novel application of kaempferol as a synergist of anti-fungal medicaments. The anti-fungal medicaments are azole-type or polyene-type anti-fungal medicaments and based on the effective concentration of the anti-fungal medicaments, the adding ratio of the kaempferol is 0.5 to 16 mu g / ml. Tests show that when the kaempferol and the anti-fungal medicaments such as fluconazole, ketoconazole, miconazole and amphotericin B are used together, not only the anti-fungal effect is guaranteed on the premise of lowering the consumption of the anti-fungal medicaments, but also the anti-fungal medicaments can restore the function of killing the drug-resistant fungi, so that the kaempferol can be used as a synergist of the anti-fungal medicaments. The kaempferol used as the synergist of the anti-fungal medicaments can lower the consumption of the azole-type or polyene-type anti-fungal medicaments so as to reduce the toxic and side effects of the medicaments; and the kaempferol can make the anti-fungal medicaments restore the function of killing the drug-resistant fungi, so that the kaempferol can effectively treat mycotic infection, particularly drug-resistant t mycotic infection, and has quite important clinical application values.

The invention discloses a nucleic acid protective liquid and an application thereof for long-term storage and transportation of a tissue sample at constant temperature. The nucleic acid protective liquid comprises the following components: D-glucose, 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid, inorganic salt, amino acids, choline chloride, folic acid, nicotinamide, inositol, vitamin A, vitamin H, vitamin E, Holo-human transferrin, bovine serum albumin, N-(2)-L-alanyl-L-glutamine, insulin, adrenalone, linoleic acid, linolenic acid, progesterone, penicillin, streptomycin, amphotericin B and water. The nucleic acid protective liquid is low in cost. By using the nucleic acid protective liquid, nucleic acid in the tissue sample is long in storage time at room temperature, and the obtained nucleic acid is high in concentration and great in total amount. A preparation method for the nucleic acid protective liquid is simple and fast.

Provided are cosolvent evaporation methods and compositions for improving the solubility of hydrophobic compounds, including therapeutic agents such as anticancer drugs, polyene antibiotics, antilipidemic agents, and hydrophobic compounds used in various industries, and / or for reducing the toxicity of certain hydrophobic therapeutic agents, especially polyene antibiotics, in particular, Amphotericin B (AmB), and therapeutics such as paclitaxel, tamoxifen, an acylated prodrug or an acylated cis-platin, by incorporating these agents within micelles comprising an amphiphilic block-forming copolymer.

The invention relates to a novel broad-spectrum antifungal medicine compound, a broad-spectrum antifungal medicine composition, an application of the compound or the composition in the preparation of a broad-spectrum antifungal medicine, and an application of the compound or the composition in the preparation of a medicine used for treating severe invasive infection (comprising Candida krusei) caused by invasive aspergillosis and / or Fluconazole-resistant Monilia and / or severe infection caused by Scedosporium and fusarium. The novel broad-spectrum antifungal medicine compound and the broad-spectrum antifungal medicine composition have extensive and strong antifungal activity and better dynamic property and safety. For deep mycotic infection, the novel broad-spectrum antifungal medicine compound and the broad-spectrum antifungal medicine composition are better than the original voriconazole in the aspects of the antibiotic activity and the medicine resistance and is better than amphotericin B in the aspects of safety and effectiveness; and compared with the formerly applied voriconazole, Fluconazole, itraconazole and amphotericin B, the novel broad-spectrum antifungal medicine compound and the broad-spectrum antifungal medicine composition have reinforced medicine effect, less adverse reaction and good safety.

The invention provides a preserving fluid for preserving a virus sample at normal temperature for a long time. The preserving fluid is equipped whit nutrient substances such as salts, amino acids, glucose and the like required by virus survival, is added with virus protective agents such as polyvinylpyrrolidone, mannitol, trehalose and the like for protecting viruses, and is added with bacteriostatic agents such as amphotericin B, vancomycin and the like for inhibiting the growth of bacteria. The preserving fluid is safe and non-toxic, is simple to use, does not need cold chain preservation, can be used for transporting and preserving the virus sample at normal temperature for 3 days, and effectively solves the problems that the virus samples depend on cold chains in the sampling, transporting and preserving processes and the preservation time is short. The preserving fluid can maintain the primitiveness of the virus sample, is beneficial to comprehensive analysis and research of the virus sample, and is suitable for collection and transportation of epidemic virus samples.

An inhalable formulation of amphotericin B and a hydrofluoroalkane propellant in for pressurized metered dose aerosol canisters is provided. Also provided are methods for administering amphotericin B to the upper or lower respiratory tract of a patient with this inhalable formulation and a pulsatile nasal administration device for delivery of medications packaged in a metered dose aerosol canister to the paranasal sinuses.

The invention relates to preservation of human local living parts and in particular relates to a culture medium for keeping primary airway epithelial cells in the physiological state in vivo during in vitro culture. The invention is characterized in that the culture medium contains the following components (per liter), 12 g of DMEM / F12 medium, 30 mg of penicillin G sodium salt, 50 mg of streptomycin, 10 mg of insulin, 5 mg of transferring, 25 Mug of epidermal growth factors, 100 Mug of cholera toxin, 108.741 Mug of hydrocortisone, 1 g of bovine pituitary extract, 3 g of bovine serum albumin, 1.5*10<-2> Mug of retinoic acid, 50 mg of gentamycin, 0.5 mg of amphotericin B, 50 mL of fetal calf serum and the balance of water. The primary airway epithelial cells cultured by the culture medium have the ciliary beating function and can maintain the physiological state in vivo.

The invention discloses colorectal cancer solid tumor tissue sample preserving fluid. The colorectal cancer solid tumor tissue sample preserving fluid is prepared from fetal calf serum, three antibacterial and antifungal agent antibodies, HEPES and the balance of HBSS, wherein by volume fraction, the final concentration of the fetal calf serum is 1-5%, the final concentration of penicillin in thethree antibacterial and antifungal agent antibodies is 100-200 U / mL, the final concentration of streptomycin in the three antibacterial and antifungal agent antibodies is 100-200 [mu]g / mL, the final concentration of amphotericin B in the three antibacterial and antifungal agent antibodies is 250-500 ng / mL, and the final concentration of the HEPES is 8-12 mM. A colorectal cancer primary cell culture obtained through a method can be used for in-vitro experiment, next-generation sequencing, animal model construction, cell line construction and the like at various cell levels; and it can be foreseen that the culture method and the sample preserving fluid provided by the invention have wide application prospects in the fields of colorectal cancer research and clinical diagnosis and treatment.

The invention provides an in-vitro tooth preservation liquid for preserving in-vitro teeth and ensuring the activity of tooth cells. Every 1L of the in-vitro tooth preservation liquid consists of the following components: 0.3-0.6g of penicillin, 0.5-1g of streptomycin, 0.02-0.04g of metronidazole, 0.015-0.025g of amphotericin B, 5-10g of hydroxymethyl cellulose, 50-100mu g of insulin and the balance of MEM. The in-vitro tooth preservation liquid can provide nutrient substances and low-bacterial environments requested by in-vitro teeth, can effectively maintain the activity of cells, and can be used for preserving in-vitro teeth for a long time.

The invention relates to the field of biotechnology, in particular to an organoid culture medium and an organoid culture method. The organoid culture medium comprises a base medium, hydrothorax supernatant, enzyme hydrolyzed casein, hydrocortisone, l-glutamic acid, insulin, transferrin, cholera viruses, Y-27632, EGF, amphotericin B, penicillin and streptomycin. The organoid culture method includesperforming two-dimensional culture on tumor cells, and performing three-dimensional culture on the cultured cells to form organoid tissue. The medium formula can promote the rapid proliferation of tumor tissue while avoiding hypoxia injuries, and the culture method can greatly shorten the time required for a subsequent drug sensitivity test; the accuracy of the drug sensitivity test is improved,and the test cost is reduced.

The invention provides a culture medium for stomach cancer organs and a culture method. The culture medium comprises a basic culture medium 1640, specific addition factors and sterile water, wherein the mass ratio of the basic culture medium 1640 to the sterile water is 99:1; and the specific addition factors comprise B27 without vitamin A, N-acetylcysteine, EGFs (epidermal growth factors), Noggin, R-spondin 1, Wnt3a, CHIR99021, thiazovivin, Gastrin I, valproic acid, a penicillin and streptomycin mixed liquid, amphotericin B and Primocin. The culture medium can be adopted to culture the stomach cancer organs, morphology structures and gene characteristics of primary tissue can be maintained, the risk of microorganism pollution in stomach cancer culture can be effectively reduced, and the success rate and the survival rate of stomach cancer organ culture can be increased.

Described are compounds and methods useful for selectively targeting cancer stem cells. The compounds preferentially induce differentiation and / or reduce the proliferation of cancer stem cells relative to normal stem cells. Compounds useful for selectively targeting cancer stem cells include polyene macrolides such as Nystatin or Amphotericin B, analogs thereof and pharmaceutically acceptable salts thereof.

The invention belongs to the technical field of medicine, and more specifically provides applications of nicotinamide in preparing an antifungal drug synergist. Novel applications of nicotinamide are provided; nicotinamide is capable of reducing dosages of antifungal drugs such as azoles, echinocandins, and polyenes as an antifungal drug synergist, and reducing toxic and side effect of drugs, especially fluconazole, voriconazole, caspofungin, and amphotericin B, accordingly. Nicotinamide is capable of recovering the effect of antifungal drugs on drug resistance funguses as a antifungal drug synergist, treating fungal infection especially drug resistance fungus infection effectively, reducing drug toxicity, and reducing economic burden of patients in drug therapy; and in addition, nicotinamide is capable of improving the effect of antifungal drugs on candida tropicalis and cryptococcus neoformans, and possesses high clinical application value.

The present invention provides new polyene macrolide derivatives which show very low toxicity while retaining high antifungal activity as compared with amphotericin B (AmB). These polyene macrolide derivatives comprise a polyene macrolide backbone having at least one free amino group, wherein the amino group is doubly alkylated with at least one hydrocarbon group carrying a total of at least two basic groups.

Belonging to the field of biotechnology, the invention in particular relates to an amphotericin B polypeptide hydrogel drug carrier system for treatment of fungal infection. According to the invention, polypeptide hydrogel with great clinical application potential is employed for covalent binding of small molecule hydrophobic antibacterial drug amphotericin B to form the amphotericin B polypeptide hydrogel nano-drug carrier system. The prepared nano-drug carrier system has the characteristics of high drug loading capacity, high biocompatibility and high stability, at the same time has the advantages of sustained or controlled release of drugs, easy degradation of polypeptide carrier, reduced clinical toxic and side effects and obvious antifungal effect. The amphotericin B polypeptide hydrogel nano-drug carrier system can be stored and used in the form of amphotericin B polypeptide hydrogel nano-drug carrier system, also can be diluted with water for injection so as to be suitable for intravenous injection, or can be incorporated with other auxiliary materials to be prepared into tablets, pills, granules or capsules. The amphotericin B polypeptide hydrogel nano-drug carrier system provided by the invention is suitable for the antifungal and fungal infection disease treatment field, and has good application prospect.

The present invention relates to a nano preparation of antimycotic amphotericin B (AmB). Said invention is made up by using n-butyl poly cyanoacrylate as carrier material of AmB. The animal tests show that it can permeate through blood-brain barrier, the measured medicine concentration in brain tissue is higher than that of AmB liposome preparation in clinical application, said nano preparation of antimycotic amphotericin B (AmB) is superior to AmB liposome preparation in therapeutic effect.